TISIDB

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Melanosome membrane Multi-pass membrane protein
Domain	-
Function	Melanocyte differentiation antigen. May transport substances required for melanin biosynthesis (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006582 melanin metabolic process GO:0007601 visual perception GO:0008643 carbohydrate transport GO:0015766 disaccharide transport GO:0015770 sucrose transport GO:0015772 oligosaccharide transport GO:0018958 phenol-containing compound metabolic process GO:0019748 secondary metabolic process GO:0042438 melanin biosynthetic process GO:0042440 pigment metabolic process GO:0043473 pigmentation GO:0044550 secondary metabolite biosynthetic process GO:0046148 pigment biosynthetic process GO:0046189 phenol-containing compound biosynthetic process GO:0048066 developmental pigmentation GO:0050953 sensory perception of light stimulus GO:1901615 organic hydroxy compound metabolic process GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function	GO:0005351 sugar:proton symporter activity GO:0005402 cation:sugar symporter activity GO:0008506 sucrose:proton symporter activity GO:0008515 sucrose transmembrane transporter activity GO:0015144 carbohydrate transmembrane transporter activity GO:0015154 disaccharide transmembrane transporter activity GO:0015157 oligosaccharide transmembrane transporter activity GO:0015291 secondary active transmembrane transporter activity GO:0015293 symporter activity GO:0015294 solute:cation symporter activity GO:0015295 solute:proton symporter activity GO:0022804 active transmembrane transporter activity GO:0051119 sugar transmembrane transporter activity GO:1901476 carbohydrate transporter activity
Cellular Component	GO:0030659 cytoplasmic vesicle membrane GO:0033162 melanosome membrane GO:0042470 melanosome GO:0045009 chitosome GO:0048770 pigment granule

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5662702: Melanin biosynthesis R-HSA-1430728: Metabolism R-HSA-71291: Metabolism of amino acids and derivatives

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SLC45A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SLC45A2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
28630054	Melanoma	Immunotherapy target	Antigen-specific CTLs generated against HLA-A0201- and HLA-A2402-restricted SLC45A2 peptides effectively killed a majority of HLA-matched cutaneous, uveal, and mucosal melanoma cell lines tested (18/25).

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SLC45A2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SLC45A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.909	0.402
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	3.216	0.224
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.788	0.726
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.388	0.597
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.035	0.978
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.922	0.536
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.345	0.719
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-1.196	0.519
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	2.017	0.324
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.556	0.279
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.762	0.267
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.231	0.293

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SLC45A2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC45A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC45A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC45A2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC45A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SLC45A2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SLC45A2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SLC45A2
Name	solute carrier family 45, member 2
Aliases	OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location	5p13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SLC45A2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SLC45A2